On the Surface, a Smarter Approach

Treating patients systemically can lead to unwanted effects in the body owing to a lack of specificity and the need for high doses. At Pulmocide, we aim to deliver novel antiviral and antifungal treatments delivered easily and directly to the lung to maximize efficacy and minimize adverse effects.

More
Novel inhaled respiratory medicine development pipeline.

We are developing novel, potent first-in-class anti-infective agents for delivery by inhaled administration for life-threatening lower respiratory infections.

more

Management Team

  • Dr Garth Rapeport
    More
  • Dr Pete Strong
    More
  • Dr Alison Murray
    More
  • Dr Kaz Ito
    More
  • Dr John Murray
    More
  • Dr Lindsey Cass
    More
  • Dr Amanda Davis
    More

Investors